{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"}]}],"title":"Decrease to <=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"27"},{"groupId":"OG007","value":"8"}]}],"title":"Change to normal/No change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"}]}],"title":"Increase to >=38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \\<=35 degree Celsius and \\>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure","title":"Number of Participants With Changes in Temperature From Baseline-Part 1 QD","type":"PRIMARY","unitOfMeasure":"Participants"}